DBV Technologies | DBVT - Cash And Equivalent


DBV Technologies reported $69.84M in Cash and Equivalent for its fiscal quarter ending in September of 2025.





Cash And Equivalent Change Date
Acadia Pharmaceuticals USD 847.02M 85.02M Sep/2025
Alnylam Pharmaceuticals USD 1.49B 376.56M Sep/2025
Amarin USD 122.8M 25.08M Sep/2025
BioMarin Pharmaceutical USD 1.25B 36.29M Sep/2025
DBV Technologies USD 69.84M 33.37M Sep/2025
Halozyme Therapeutics USD 419.66M 357.8M Sep/2025
Incyte USD 2.93B 508.08M Sep/2025
Insmed USD 334.76M 949.56M Sep/2025
Ionis Pharmaceuticals USD 2.24B 1.94B Sep/2025
Neurocrine Biosciences USD 340.2M 76.2M Sep/2025
PTC Therapeutics USD 672.62M 344.77M Sep/2025
Sarepta Therapeutics USD 613.08M 102.48M Sep/2025
Ultragenyx Pharmaceutical USD 202.51M 36.4M Sep/2025
United Therapeutics USD 1.34B 253M Sep/2025